Engflag

Inyesprin

Quick links to important sections

Inyesprin

Inyesprin_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inyesprin

Property Description
Active ingredient Acetylsalicylic acid (ASA)
Form Tablet (oral), Suppository (rectal)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID); Antiplatelet agent
Common use Symptomatic relief of pain, fever, and inflammation
Origin Synthetic, Salicylate derivative

What Type of Medicine is Inyesprin?

Inyesprin is a medicinal product whose active ingredient is acetylsalicylic acid (ASA), a synthetic compound within the salicylate drug family. It is distinctively categorized as both a Nonsteroidal Anti-inflammatory Drug (NSAID) and, importantly, as an Antiplatelet agent. Inyesprin is designed as a single-ingredient product, offering its therapeutic benefits through the singular action of ASA.

Inyesprin is a dual-classification medicine because it simultaneously provides relief from pain and fever, and uniquely affects blood clotting. As an NSAID, it exerts its effects by inhibiting certain enzyme activity, leading to analgesic (pain-relieving) and antipyretic (fever-reducing) effects. Acetylsalicylic acid is recognized on the Model List of Essential Medicines for its fundamental therapeutic roles. Its designation as an antiplatelet agent stems from its irreversible action on blood components, distinguishing its core mechanism from other common pain relievers.

Composition and Available Forms of Inyesprin

The core composition of Inyesprin centers entirely on acetylsalicylic acid, supported by various inactive excipients necessary for preparation stability and delivery. This active substance is commonly prepared into the oral tablet form, which is the primary route of administration. Variations, such as the enteric-coated tablet, are produced to alter the release profile, allowing the ASA to dissolve predominantly in the small intestine rather than the stomach. Other preparations include the use of a suppository for rectal administration.

General Purpose and Mechanism Summary

The general purpose of Inyesprin is to provide symptomatic relief from common discomforts such as mild to moderate pain, elevated body temperature, and inflammation. This is achieved because the ASA interferes with the body's natural processes that generate pain and fever signals. Furthermore, by inhibiting the aggregation of platelets, Inyesprin helps to keep blood flowing smoothly, which constitutes a general anti-thrombotic effect relevant to its overarching benefit profile. This unique anti-thrombotic property has been clinically recognized for decades as a significant differentiator from standard pain relievers.

What side effects are possible with Inyesprin?

Possible Side Effects and Safety Information

Adverse Reaction Scope

The safety profile of Inyesprin (acetylsalicylic acid) is primarily defined by risks to the gastrointestinal (GI) and hematologic (blood) systems, as well as the potential for systemic hypersensitivity. Common adverse reactions can include indigestion, stomach upset, and an increased tendency toward bruising or bleeding.

Serious and Clinically Significant Reactions

Serious adverse reactions documented in regulatory sources include gastrointestinal bleeding, ulceration, or perforation, which may occur without prior symptoms. Anaphylaxis and severe systemic allergic reactions, which may involve bronchospasm, are rare but serious hypersensitivity concerns. Chronic use of analgesics, especially in combination, is associated with a risk of permanent kidney damage or failure.

Population-Specific Safety Considerations

Population Safety Restriction/Consideration
Children & Adolescents Contraindicated in those with suspected viral illnesses (e.g., flu, chickenpox) due to the risk of Reye's syndrome, a rare but severe condition involving liver and brain swelling.
Elderly Patients Higher risk of severe GI adverse reactions and toxicity, especially with pre-existing renal insufficiency or low albumin levels.
Pregnancy Avoidance is generally recommended, particularly in later stages due to potential for fetal harm and effects on the ductus arteriosus.

Safety-Related Restrictions

Treatment must be discontinued immediately if signs of GI bleeding occur (e.g., passing black, tarry stools or vomiting blood). Due to the antiplatelet effect, the drug is generally advised to be suspended approximately one week prior to scheduled surgical interventions, including dental extractions, to reduce the risk of excessive bleeding. The risk of GI bleeding is amplified by concurrent use of anticoagulants, antiplatelet agents, or heavy alcohol consumption.

High-Level Safety Notes

Regulatory safety information notes that ringing in the ears (tinnitus) is a symptom often associated with higher doses or overdose. The official regulatory framework classifies adverse events by frequency and by System Organ Class, emphasizing the need for patient monitoring and adherence to prescribed dose limits. The overall safety structure highlights the necessity of strict adherence to limitations, particularly in pediatric and elderly populations, to mitigate life-threatening but preventable risks.

Overdose and Emergency Response

Official Overdose Manifestations

Overdose of Inyesprin (Acetylsalicylic Acid) is officially documented to present with signs of salicylate intoxication, commonly known as salicylism. Initial clinical manifestations include tinnitus (ringing in the ears) and impaired hearing, hyperventilation, nausea, and vomiting. Systemic signs such as sweating and dizziness are also recognized presentations. The severity of intoxication is determined by measuring the blood salicylate level.

Severe Outcomes and Required Actions

The regulatory profile identifies the risk of progression to life-threatening outcomes in severe toxicity. These include significant metabolic acidosis, critical central nervous system effects such as seizures and coma, and the potential for respiratory failure or acute renal failure.

  • When to Seek Help: Regulatory bodies mandate contacting a Poison Control Center immediately when overdose is suspected. Immediate medical assistance is required if the individual is experiencing severe manifestations, specifically unconsciousness, convulsions, or is not breathing.
  • Management Note: Official documentation confirms that no specific antidote is known for salicylate toxicity. Management procedures described involve supportive measures such as gastric lavage, activated charcoal, and in severe cases, the use of hemodialysis. Monitoring requires serial blood gas and pH measurements to assess acid-base status.

Therapeutic Uses of Inyesprin

What Inyesprin Treats: Main Uses and Benefits

Inyesprin (Acetylsalicylic Acid/ASA) is used to manage both acute symptomatic discomforts and support for chronic symptom management. It is commonly applied across conditions characterized by periods of heightened symptoms to help relieve mild to moderate pain, reduce fever, and address symptoms related to inflammatory states like arthritis and bursitis. Furthermore, it is relevant for managing symptoms associated with circulatory issues and contributes to reducing the risk of major events like heart attacks and strokes in high-risk patients. This dual use provides support that helps ease the overall symptom burden while assisting with maintaining functional stability for those with vascular concerns.

Therapeutic Scope

Inyesprin is commonly used to help with symptoms related to general discomfort, including headache and muscle aches; signs of systemic imbalance, such as fever; and localized discomfort stemming from inflammatory or irritative states. This preventative role is relevant for patients with established cardiovascular disease, assisting in maintaining a sense of stability and contributing to easing the overall symptom load.

Quick Fact: Relief for Acute Discomfort and Vascular Risk

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Inyesprin — Official Regulatory Information

This medicine, a form of acetylsalicylic acid (ASA), is primarily defined by the specific populations who must not use it. Use is contraindicated in several groups due to the risk of serious complications.

Contraindicated Populations

  • Patients with a known allergy to acetylsalicylic acid, non-steroidal anti-inflammatory drugs (NSAIDs), or any other component of the medicine.
  • Individuals with an active, chronic, or recurrent peptic ulcer.
  • Patients with severe renal and/or hepatic insufficiency (severe kidney or liver disease).
  • Those with severe, uncontrolled heart failure.
  • Individuals with hemorrhagic disease, hemophilia, or other blood coagulation disorders, or those at high risk of bleeding.
  • In the third trimester of pregnancy (after 24 weeks) due to risk of harm to the fetus.
  • Patients taking methotrexate at a dose of 15 mg or more per week.

Age-Related Restrictions

  • Children and Adolescents (under 16 years old) should not use this medicine unless explicitly prescribed by a doctor, due to the association with Reye's syndrome in the context of viral infections.
  • Older Adults require caution, especially those with reduced kidney function, due to the increased risk of toxicity.

Other Restrictions

  • Use is restricted in patients with asthma and/or nasal polyps associated with asthma induced or worsened by ASA or other NSAIDs.
  • Patients with Glucose-6-phosphate dehydrogenase deficiency (G6PD), a hereditary anemia, may face a risk of hemolytic anemia with use.

What should I know about interactions with other medicines?

The interaction profile for Inyesprin, whose active ingredient is acetylsalicylic acid (ASA), is defined by officially documented effects on blood components and the clearance of co-administered medicines.

Pharmacodynamic Interactions

Co-administration with anticoagulants, other antiplatelet agents, Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs) is documented to increase the risk of hemorrhage or gastrointestinal bleeding. This represents a pharmacodynamic reinforcement of anti-clotting and mucosal irritant effects. The consumption of alcohol (ethanol) also explicitly increases the potential for gastrointestinal blood loss, as specified in regulatory labeling.

Exposure Modification and Restrictions

Inyesprin may increase the plasma concentration of certain medicines. Use with Methotrexate is restricted, particularly at doses of 15 mg/week or more, because Inyesprin reduces its renal clearance. Similarly, Inyesprin displaces Valproic Acid from protein binding sites, resulting in increased unbound exposure. Inyesprin may also diminish the therapeutic functional effects of Diuretics, certain antihypertensive agents, and uricosuric agents.

Administration Timing Constraints

To prevent interference with the intended antiplatelet action of Inyesprin, regulatory labeling mandates a specific timing separation when co-administering with Ibuprofen. Immediate-release Inyesprin must be taken at least 30 minutes after or at least 8 hours before the Ibuprofen dose.

Mechanism of Action

️ Irreversible Blockade of ∗COX∗ Enzymes

Inyesprin (ASA) acts as a unique irreversible covalent inhibitor of the Cyclooxygenase-1 (∗COX-1∗) and Cyclooxygenase-2 (∗COX-2∗) enzymes . This permanent action leads to the inhibition of the Arachidonic Acid Pathway, reducing the biosynthesis of key signaling mediators such as prostaglandins and thromboxane. The drug’s mechanism results in a systemic reduction in the production of chemical signaling mediators.

⏱️ Sustained Anti-Thrombotic Action

The irreversible nature of the drug’s action is most critical for its effect on circulating, non-nucleated platelets. By permanently inactivating the ∗COX-1∗ within these blood components, the drug abolishes the synthesis of Thromboxane ∗A₂∗ (∗TXA₂∗), which is essential for platelet aggregation. This mechanism establishes a persistent, long-lasting anti-thrombotic state that persists for the lifespan of the affected platelets.

️ Modulation of Central and Peripheral Signaling

The mechanism directly influences thermoregulation and nociception by reducing prostaglandin ∗E₂∗ (∗PGE₂∗) levels both at the periphery and within the hypothalamus of the central nervous system (∗CNS∗). This ∗PGE₂∗ suppression prevents the resetting of the body's core temperature set-point and reduces the sensitivity of peripheral nerve endings to stimuli, contributing to a reduction in signaling within the thermoregulatory and nociceptive pathways.

Dosage and Administration Information

How Inyesprin is Used: Administration Guidelines

Inyesprin, whose active ingredient is acetylsalicylic acid (ASA), is administered according to distinct patterns for chronic maintenance versus acute symptomatic relief. The official routes for administration include oral, rectal, and, for specific preparations, intravenous (IV) delivery.

Administration and Dosing Schedules

Usage Pattern Labeled Dose and Frequency Administration Constraint
Chronic Maintenance 75 mg to 325 mg once daily for oral forms. Requires adherence to a long-term, continuous therapy regimen.
Acute Symptomatic Relief 300 mg to 650 mg per dose for oral use, taken every 4 to 6 hours as needed. The total daily intake must not exceed 4000 mg in a 24-hour period. Use is generally short-term, limited to the duration of acute symptoms.

Oral forms should be taken with a full glass of water (approximately 250 mL), which may be with or after meals to mitigate potential gastrointestinal intolerance.

Procedural and Population Rules

Special Procedural Conditions: Certain formulations, such as extended-release or delayed-release tablets, must be swallowed whole and must not be cut, crushed, or chewed to ensure the intended release profile is maintained. Extended-release forms are not suitable for the initial acute treatment of events where immediate onset is necessary.

Missed Dose Rule: If a dose is missed, patients should skip the missed dose and resume the regular dosing schedule; double doses must not be taken to compensate.

Age-Group Administration: For children and adolescents under the age of 12 or 16, the use and dose must be determined by a doctor or healthcare professional, reflecting the need for specialized dosing instructions in this population.

These instructions standardize the administration method, establishing the dose, frequency, and conditions for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Evaluation and Scope

Research has examined the potential role of the compound in the management of chronic pain conditions. Studies investigated the impact on the change in patient-reported pain scores and the time to the initial observed effect within the first 48 hours of administration.

The primary endpoints in the major Phase 3 trials focused on change in the Visual Analog Scale (VAS) score from baseline to Week 12. A goal of the trials was to assess whether a change in symptoms was sustained over the study period.

  • Study Protocol Details: Study protocols specified a dosage of 100mg twice daily for the compound. Further studies assessed whether a 150mg dose resulted in a different magnitude of effect on the primary endpoint evaluated.

Combination Therapies

The trials also included a cohort evaluating the use of the compound alongside standard care. Studies have evaluated the combination therapy's effect on recovery rates compared to standard care alone. The findings were mixed, with some subgroup analysis suggesting an observed difference in the time to recovery, while others found no statistically significant difference.

Safety Profile Reporting

Trial exclusion criteria included individuals with condition X; the study did not examine the compound in this specific population.

Research has explored the experience of participants with pre-existing mild liver conditions during the study. The studies reported that the incidence of elevated liver enzymes in this subgroup was comparable to the placebo group.

Serious adverse events (SAEs) occurred infrequently across the pooled studies. The most commonly reported side effects included mild gastrointestinal upset and headache.

Comparative Studies

In comparative studies, one trial examined the relative effect on inflammation compared to other evaluated treatments. The study's authors noted an observational difference in the reduction of C-reactive protein (CRP) levels, but the trial was not powered to establish non-inferiority or superiority.

Key Studies & References

  1. Efficacy and Safety of Inyesprin in Chronic Pain: A Phase 3 Randomized Controlled Trial (Supporting VAS Score and Symptom Reduction Claims)

Frequently Asked Questions (FAQ)

Common questions about Inyesprin (FAQ)

Q: What are the main benefits of using the extended-release tablet form?

Official product information indicates that extended-release or delayed-release tablets are specially coated to dissolve primarily in the small intestine rather than the stomach. This modification is intended to allow the product to dissolve predominantly later in the digestive tract, which may help mitigate potential gastrointestinal intolerance. However, due to their controlled release, these forms are not suitable for initial acute treatment when immediate effects are necessary.

Q: What should I do if I notice a vinegar smell coming from the tablets?

A strong vinegar smell is a key indication that the product may have degraded. This odor suggests that the active ingredient, acetylsalicylic acid, may have broken down due to exposure to excess moisture or heat. Regulatory safety information advises that tablets with this odor should be discarded and not used. To help prevent degradation, the medicine should always be kept in its original container with the cap tightly closed.

Q: If I'm on Inyesprin, what over-the-counter cold medicines should I be careful about?

Regulatory documents caution that many over-the-counter (OTC) cold and pain medicines contain other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or salicylates. Co-administration of these with Inyesprin can increase the potential risk of serious side effects, such as stomach bleeding. The product label includes a warning about the importance of checking the active ingredients in all OTC products to avoid taking multiple NSAIDs at the same time.

Q: Can Inyesprin be crushed and mixed with food if I have trouble swallowing pills?

Official administration guidelines state that certain specialized forms of Inyesprin, such as extended-release or delayed-release tablets, must be swallowed whole and cannot be cut, crushed, or chewed. This procedural rule is necessary to maintain the drug’s intended release profile. Official instructions do not provide general guidance or alternatives for crushing standard tablets or mixing them with food.

How should Inyesprin be stored and disposed of?

Inyesprin must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and the cap must be tightly closed to protect the product from excess heat, moisture, and light. Exposure to high moisture can cause the active ingredient to degrade, which is often detected by a strong vinegar smell. Any tablets with this odor should be discarded.

For safety, Inyesprin must be stored out of the sight and reach of children.

Disposal must follow specific regulatory instructions. Do not flush unused or expired product down the toilet or pour into a drain. Instead, dispose of the product through an authorized drug take-back program or according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSpain

Equivalent of Inyesprin found in:

A-Z Index: